Bjelić Dragana, Finšgar Matjaž
Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, 2000 Maribor, Slovenia.
Pharmacol Res. 2022 Feb;176:106060. doi: 10.1016/j.phrs.2022.106060. Epub 2022 Jan 6.
The use of therapeutic agents that inhibit bone resorption is crucial to prolong implant life, delay revision surgery, and reduce the burden on the healthcare system. These therapeutic agents include bisphosphonates, various nucleic acids, statins, proteins, and protein complexes. Their use in systemic treatment has several drawbacks, such as side effects and insufficient efficacy in terms of concentration, which can be eliminated by local treatment. This review focuses on the incorporation of osteoclast inhibitors (antiresorptive agents) into bioactive coatings for bone implants. The ability of bioactive coatings as systems for local delivery of antiresorptive agents to achieve optimal loading of the bioactive coating and its release is described in detail. Various parameters such as the suitable concentrations, release times, and the effects of the antiresorptive agents on nearby cells or bone tissue are discussed. However, further research is needed to support the optimization of the implant, as this will enable subsequent personalized design of the coating in terms of the design and selection of the coating material, the choice of an antiresorptive agent and its amount in the coating. In addition, therapeutic agents that have not yet been incorporated into bioactive coatings but appear promising are also mentioned. From this work, it can be concluded that therapeutic agents contribute to the biocompatibility of the bioactive coating by enhancing its beneficial properties.
使用抑制骨吸收的治疗药物对于延长植入物寿命、推迟翻修手术以及减轻医疗保健系统负担至关重要。这些治疗药物包括双膦酸盐、各种核酸、他汀类药物、蛋白质和蛋白质复合物。它们在全身治疗中的应用存在若干缺点，如副作用以及在浓度方面疗效不足，而局部治疗可以消除这些缺点。本综述重点关注将破骨细胞抑制剂（抗吸收剂）纳入骨植入物的生物活性涂层。详细描述了生物活性涂层作为抗吸收剂局部递送系统实现生物活性涂层最佳负载及其释放的能力。讨论了各种参数，如合适的浓度、释放时间以及抗吸收剂对附近细胞或骨组织的影响。然而，仍需要进一步研究以支持植入物的优化，因为这将有助于随后在涂层材料的设计和选择、抗吸收剂的选择及其在涂层中的用量方面进行个性化涂层设计。此外，还提到了尚未纳入生物活性涂层但前景看好的治疗药物。从这项工作可以得出结论，治疗药物通过增强生物活性涂层的有益特性来促进其生物相容性。
